Extended indication Amyotrophic lateral sclerosis (ALS), add on in patients on a stable dose of riluzole.
Therapeutic value No judgement

Product

Active substance Masitinib
Domain Neurological disorders
Main indication ALS
Extended indication Amyotrophic lateral sclerosis (ALS), add on in patients on a stable dose of riluzole.
Proprietary name Masipro
Manufacturer AB Science
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)
Additional remarks Al als diergeneesmiddel op de markt sinds 2009 voor behandeling van mast-cel tumoren (Masivet).

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date September 2016
Orphan drug Yes

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.